Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 530 Fairview Ave N SEATTLE WA 98109-5553 |
Tel: | N/A |
Website: | https://www.nanostring.com |
IR: | See website |
Key People | ||
William D. Young Independent Chairman of the Board | R. Bradley Gray President, Chief Executive Officer, Director | K. Thomas Bailey Chief Financial Officer |
John Chad Brown Senior Vice President - Sales and Marketing | Joseph M. Beechem Senior Vice President - Research and Development | David W. Ghesquiere Senior Vice President - Corporate and Business Development |
Business Overview |
NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company's nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. |
Financial Overview |
For the nine months ended 30 September 2020,NanoString Technologies Inc revenues decreased 9% to$81.1M. Net loss increased 35% to $87.1M. Revenues reflecta decrease in demand for the Company's products andservices due to unfavorable market conditions. Higher netloss reflects Interest expense increase of 84% to $11.2M(expense), Interest income decrease of 28% to $1.5M(income). |
Employees: | 551 as of Dec 31, 2019 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,024M as of Sep 30, 2020 |
Annual revenue (TTM): | $117.99M as of Sep 30, 2020 |
EBITDA (TTM): | -$86.10M as of Sep 30, 2020 |
Net annual income (TTM): | -$63.09M as of Sep 30, 2020 |
Free cash flow (TTM): | -$103.18M as of Sep 30, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 44,065,328 as of Nov 2, 2020 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |